PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
59.45%
Revenue growth similar to ACB.TO's 54.98%. Walter Schloss would see if both companies share industry tailwinds.
-53.84%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-103.69%
Negative EBIT growth while ACB.TO is at 34.91%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-103.69%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
153.01%
Net income growth above 1.5x ACB.TO's 32.04%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
141.84%
Positive EPS growth while ACB.TO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
141.84%
Positive diluted EPS growth while ACB.TO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
8.51%
Share reduction more than 1.5x ACB.TO's 44.41%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
8.22%
Diluted share reduction more than 1.5x ACB.TO's 42.92%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
89.50%
Positive OCF growth while ACB.TO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
24.16%
Positive FCF growth while ACB.TO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.82%
3Y CAGR of 63.82% while ACB.TO is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
-109.34%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-273.64%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-202.53%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
3051.78%
Net income/share CAGR 1.25-1.5x ACB.TO's 2370.85%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
11082.24%
5Y net income/share CAGR above 1.5x ACB.TO's 4942.85%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
2188.69%
3Y net income/share CAGR above 1.5x ACB.TO's 1163.39%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
3410.56%
10Y equity/share CAGR at 75-90% of ACB.TO's 4185.79%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
16854.11%
5Y equity/share CAGR 1.25-1.5x ACB.TO's 12169.10%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
448.58%
Below 50% of ACB.TO's 19687.53%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.98%
AR growth is negative/stable vs. ACB.TO's 184.94%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
13.55%
Inventory shrinking or stable vs. ACB.TO's 97.51%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
26.26%
Asset growth well under 50% of ACB.TO's 159.35%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
10.83%
Under 50% of ACB.TO's 95.05%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-3.57%
We’re deleveraging while ACB.TO stands at 43.25%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
128.48%
R&D dropping or stable vs. ACB.TO's 271.18%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
15.04%
SG&A declining or stable vs. ACB.TO's 75.32%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.